Follow us on:

Linkedin Facebook

hVIVO to hold AGM on 13 May 2024

hVIVO plc

hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has confirmed that the Company’s Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting will be posted to shareholders today.

The 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company’s website www.hvivo.com.

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 13 May 2024 at 11am (BST).

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

hVIVO plc

hVIVO to host Final Results Analyst Briefing on 10 April 2025

hVIVO plc (LON:HVO), a leader in human challenge clinical trials, will announce its 2024 results on April 10, 2025, with an analyst briefing to follow.
hVIVO

hVIVO expands hLAB and biobank service with Cryostore acquisition

hVIVO plc, a leader in human challenge clinical trials, has acquired Cryo-Store Limited to enhance its biobank and laboratory services with advanced storage solutions.
hVIVO

hVIVO signs new £2 million hMPV characterisation study contract

hVIVO plc secures a £2 million contract post-successful hMPV trial, advancing critical human challenge studies for future vaccine development.
Open Orphan

hVIVO reports positive results from RSV antiviral human challenge trial with Shionogi

hVIVO plc, a leader in human challenge clinical trials, reports successful Phase 2a results for Shionogi's RSV antiviral, S-337395, showing significant efficacy.
hVIVO

hVIVO and Inhalon Biopharma partner to test inhaled antiviral for RSV

hVIVO plc partners with Inhalon Biopharma to test IN-002, an inhaled antiviral for RSV, in a Phase 2a trial using their RSV Human Challenge Model.
hvivo plc

hVIVO plc Acquires two Clinical Research Units from CRS for €10.0m

hVIVO expands its clinical footprint by acquiring CRS, a German CRO, adding Phase I & II trial capabilities in Europe, enhancing strategic growth for 2025-2026.

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.